GUILLAIN-BARRÉ SYNDROME(GBS): A REVIEW

*Sakshi R. Dhone, Dr. Shivshankar D. Mhaske, Prof. Zameer M. Shah Sir Rutuja R. Tonde, Arpita S. Thakare and Samruddhi B. Deshmukh

ABSTRACT

This review article provides overview of introduction of Guillain-Barré Syndrome(GBS), epidemiology, etiology, symptoms, pathology, diagnosis and treatment Guillain-Barré Syndrome(GBS). Guillain-Barré syndrome (GBS) is a reversible but maybe deadly disease. The most common cause of acquired neuromuscular weakness internationally is a monophasic polyradiculoneuropathy that is immune-mediated and usually postinfectious. The immunopathological mechanism causing nerve damage is typically unclear. GBS is diagnosed based on clinical characteristics, which are supported by electrophysiological and laboratory results. Previously separated into primary demyelinating or axon adaptations, this distinction is becoming more and more contested, and the most recent guidelines from the European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) do not support it. Regardless of the electrophysiological subtype, the major therapeutic techniques continue to be intravenous immuneglobulin and plasma exchange. The majority of patients recover, although 5% pass away and about one-third need artificial breathing. The possible function of fluid metabolites is continuously being investigated, and disease activity and therapy response are now tracked using interval neurological examination and outcome measurements. Although there are currently no novel prospective medicines for GBS that have changed clinical practice, they are being investigated. For physicians and researchers, this review offers a thorough update on the pathological and clinical features of GBS.

Keywords: Guillain-Barré Syndrome ? GBS Pathophysiology ? GBS Diagnosis ? Autoimmune Neuropathy ? GBS Treatment ? GBS and Viral Infections ? GBS and Vaccines Guillain-Barré Syndrome Etiology